Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week ® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio ® in Key Indications
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced another milestone year at the Digestive Disease Week ® (DDW) Conference, being held from May 3-6, 2025 in San Diego, California with the presentation of at least 8 abstracts supporting the clinical value of Cellvizio ® in key indications. These abstracts focus on pancreatic cystic lesions and pancreatic cancer, food intolerance, artificial intelligence, and other gastrointestinal disorders. Studies and presentations highlight how the use of Cellvizio ® directly impacts patient management and positive outcomes.
Members of Mauna Kea's executive team will be present at DDW and meeting with physicians, industry partners, and societies, and welcome the opportunity to discuss the Company's recent achievements and future opportunities as announced in recent press releases.
"Each year, DDW is a not-to-be-missed meeting bringing the entire gastroenterology healthcare community together, and we are proud yet again to have such a wide range of independent scientific abstracts and data about Cellvizio on display, especially in areas which have significant unmet patient needs,' said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. 'Cellvizio's role in the accurate classification and risk stratification of pancreatic cysts is advancing the entire field forward for the management of patients at risk of pancreatic cancer. Moreover, the body of evidence for food intolerance identification and management has grown substantially, building a large opportunity for CellTolerance ® growth.'
Highlighted featured presentations:
Saturday, May 3
12:30pm-1:30pm
Artificial Intelligence Advances Digital Pathomics for Confocal Endomicroscopy-Guided Diagnosis of Pancreatic Cysts
12:30pm-1:30pm
Intracystic Capillary Morphology as a Novel Approach to Risk Stratification of Intraductal Papillary Mucinous Neoplasms In Confocal Endomicroscopy: Limitations of Human Performance and Insights from Artificial Intelligence
3:00pm-3:15pm
Confocal Laser Endomicroscopy Captures Local, Food-Induced Reactions at the Level of the Duodenal Mucosa in Functional Dyspepsia, That Cannot Be Translated into Permeability Alterations or Changes in Mast Cell Activation Ex Vivo
4:30pm-4:45pm
Targeted Elimination Diet in Eosinophilic Esophagitis Following Identification of Trigger Nutrients Using Confocal Laser Endomicroscopy: Results from a Pilot Trial
Sunday, May 4
8:12am-8:19am
Towards Automating Risk Stratification of Intraductal Papillary Mucinous Neoplasms: Artificial Intelligence Advances Beyond Human Expertise with Confocal Laser Endomicroscopy
Monday, May 5
8:42am-8:49am
Is It Time to Refine Our Standards? Insights From a Multicenter Prospective Study on Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy (EUS-nCLE) For Diagnosing Pancreatic Cystic Lesions
10:30am-10:45am
Effects of a Multimodal Treatment Approach in Patients with Longstanding Irritable Bowel Syndrome on Symptom Relief and Barriere Integrity Targeted by Confocal Laser Endomicroscopy: An Exploratory Prospective Observational Clinical Trial
12:30pm-1:30pm
Real-Time Intestinal Barrier Assessment by Endocytoscopy and Confocal Laser Endomicroscopy Uniquely Correlates with Multiple Barrier Protein Expression and Reflects the Gut-Brain Axis
About Digestive Disease Week ®
Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. X-ray exams often serve as the entry point to diagnostic imaging, accounting for 60% of all imaging studies conducted, resulting in an ever-increasing workload for radiologists and technologists2 3. This increased demand, combined with acute staffing challenges where 80% of healthcare organizations are short-staffed and radiology technologists have the highest vacancies3, high burnout levels and work-related injuries, creates critical barriers to providing timely, effective diagnostic imaging for patients in need of X-ray imaging. GE HealthCare's new Definium Pace Select ET solves for many of these challenges by automating manual, repetitive steps and helping to reduce physical strain. The system leverages AI to ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput. 'Burdened with the stress and pressure to keep radiology departments running smoothly and profitably, we aim to empower technologists with a system that consistently makes the first image count,' said Sharad Sharma, Global General Manager, X-ray, at GE HealthCare. 'With its advanced digital capabilities and automation, Definium Pace Select ET allows technologists of all experience levels to deliver consistent high-quality images to serve the full range of anatomies and patient populations.' Easy-to-use features allow technologists to focus on patient care Building on the trusted Definium platform from GE HealthCare, the Definium Pace Select ET system brings advanced automation and workflow features to a flexible, floor-mounted system with elevating table, in-room exam control, and common user interface to assist technologists. 'This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps,' said Jyoti Gupta, PhD, President & CEO of Women's Health and X-ray at GE HealthCare. 'We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging.' The Definium Pace Select ET system brings the same high image quality typically seen in more expensive overhead tube suspension (OTS) systems to the affordability focused floor-mounted market. Designed and developed with extensive customer feedback, the system brings: Advanced automation to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries. to reduce workflow steps and physically demanding movements for technologists, potentially minimizing work-related injuries. Image variability reduction through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images. through the AI-enabled Helix™ Advanced Image Processing to provide consistent high-quality images. Prevention of errors before they occur through automated positioning, protocol selection, patient size (body habitus), and collimation via the Intelligent Workflow Suite, and a quality check prior to radiation exposure. To learn more about the new X-ray system, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. _______________________________ 1 510(k) cleared. Not CE marked. Cannot be placed on the market or put into service or used with human beings until it has been made to comply with CE marking and/or regulatory approval. Not all features available in all markets. 2 MV 2019 X-ray CR / DR Market Outlook Report) page 9, 37 3 Pearson, Dave. 'Radiology techs in especially high demand as 85% of hospitals seek 'allied' health workers', 23 Oct. 22. Expand
Business Wire
42 minutes ago
- Business Wire
Abra Dental Expands Access to Quality Care with New Paterson, NJ Office
PATERSON, N.J.--(BUSINESS WIRE)--Abra Dental, a leading provider of family and pediatric dental care, proudly announces the grand opening of its seventh location at 370 Broadway in Paterson, New Jersey. The new office is now open and accepting new patients from Paterson and the surrounding communities. Paterson Mayor André Sayegh welcomed Abra Dental's arrival, stating, 'The opening of Abra Dental is a win for Paterson residents. Increasing access to quality healthcare, especially for children and families, is vital for our city's well-being and future." Share With a commitment to providing high-quality, accessible dental care, Abra Dental's Paterson office features state-of-the-art technology and a compassionate, multilingual team skilled in serving patients of all ages. Services include preventive care, pediatric dentistry, orthodontics, emergency dental services, and more, all in a welcoming and family-friendly environment. 'We are thrilled to bring Abra Dental's mission of accessible, high-quality dental care to the families of Paterson,' said Dr. Michael Skolnick, Founder and CEO of Abra Health Group. 'Our goal is to ensure that every member of the community has access to the dental services they need to achieve and maintain healthy smiles.' Paterson Mayor André Sayegh welcomed Abra Dental's arrival, stating, 'The opening of Abra Dental at 370 Broadway is a win for Paterson residents. Increasing access to quality healthcare, especially for children and families, is vital for our city's well-being and future. We're grateful to Abra Dental for investing in our community.' Abra Dental is supported by Abra Health Group, a doctor-led dental support organization (DSO) headquartered in New Jersey. Abra Health Group provides administrative and operational support, allowing clinicians to focus on delivering excellent patient care. With a growing network across New Jersey, Pennsylvania, and Connecticut Abra Health Group is committed to expanding access to essential healthcare services in underserved communities. The new Paterson office joins a family of six Abra Dental locations throughout New Jersey, including offices in Newark, Elizabeth, Jersey City, Kearny. Abra Dental accepts most major insurance plans, including Medicaid and CHIP, helping to reduce barriers to care for local families. Appointments can be scheduled by calling (973) 221-8758 or visiting For more information about the Abra Health Group and Abra Dental please visit their respective websites at and About Abra Health Group Founded in 2008 by Doctors Michael and Brooke Skolnick, a husband-and-wife dental team, Abra Health Group includes a rapidly expanding family of dental practices. With multiple recent acquisitions and new locations opening regularly, the group includes several multi-specialty dental clinics for patients of all ages in Connecticut, New Jersey, and Pennsylvania. Our singular mission is to provide access to high-quality, affordable care to underserved communities. By firmly placing our patients first, we aim to deliver an exceptional experience as we improve their well-being. Our vision is to become a leading dental support organization to underserved communities in the areas that we serve. With over 1,000 employees across 3 states and 23 locations, our large-footprint practices can accommodate hundreds of patients every day in an inviting, comfortable environment for both patients and staff alike.
Business Wire
an hour ago
- Business Wire
Cascade Space Announces $5.9M Seed Funding to Build End-To-End Space Communication Platform
SAN FRANCISCO--(BUSINESS WIRE)--Cascade Space, the platform for end-to-end communication system design, test, and operation, today announced that it has raised $5.9 million in seed funding. The round included participation from Nova Threshold, Undeterred Capital, Y Combinator, Night Capital, Olive Capital, Valkyrie Ventures, Karman Ventures, Palm Drive Capital, Garage Capital, TRAC, Aurelia Foundry, Hawktail, Pioneer Fund, Liquid 2 Ventures, and others. Cascade Space is building tools to accelerate communication system design and test Share The funding will accelerate the development of the Cascade Portal, a platform for satellite communication system design. Cascade recently released the spacelink Python library open-source. This library contains functions for communication system analysis that is used in the Cascade Portal implementation. 'Our mission at Cascade Space is to provide tools and infrastructure for spacecraft communication system design, test, and operations that will allow our customers to ship faster with the highest levels of mission assurance,' said Jacob Portukalian, co-founder and CEO of Cascade. 'Communication system design, test, and operation is a major bottleneck for space companies, especially those going to lunar and deep space. We have a team of veteran space engineers from SpaceX and Astra and we are stoked to be building the end-to-end platform to accelerate space exploration.' About Cascade Space: Cascade Space is a space communication system company. Founded in 2025, Cascade Space is building the platform for design, test, and operation for space communication systems. For more information, visit
